PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDiazoxide choline
Diazoxide choline
Vykat (diazoxide choline) is a small molecule pharmaceutical. Diazoxide choline was first approved as Vykat xr on 2025-03-26.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Vykat
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Diazoxide choline
Tradename
Company
Number
Date
Products
VYKAT XRSOLENO THERAPEUTICS INCN-216665 RX2025-03-26
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
vykat xrNew Drug Application2025-03-26
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hyperphagia—D006963R63.2
hypoglycemia—D007003E16.2
malignant hypertensionEFO_1001031D006974—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C02: Antihypertensives
— C02D: Arteriolar smooth muscle, agents acting on
— C02DA: Thiazide derivatives acting on arteriolar smooth muscle
— C02DA01: Diazoxide
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AH: Drugs for treatment of hypoglycemia
— V03AH01: Diazoxide
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prader-willi syndromeD011218Orphanet_739Q87.11——4——4
SyndromeD013577————4——4
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ObesityD009765EFO_0001073E66.9—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDiazoxide choline
INN—
Description
Diazoxide can cause developmental toxicity according to state or federal government labeling requirements. Diazoxide is a benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies. It has a role as an antihypertensive agent, a sodium channel blocker, a vasodilator agent, a K-ATP channel agonist, a beta-adrenergic agonist, a cardiotonic drug, a bronchodilator agent, a sympathomimetic agent and a diuretic. It is a benzothiadiazine, a sulfone and an organochlorine compound.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC1=Nc2ccc(Cl)cc2S(=O)(=O)[N-]1.C[N+](C)(C)CCO
Identifiers
PDB—
CAS-ID1098065-76-9
RxCUI—
ChEMBL IDCHEMBL4297276
ChEBI ID—
PubChem CID3019
DrugBankDB01119
UNII ID—
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use